Funding research into RMS

A diagnosis of Rhabdomyosarcoma (RMS) is a truly devastating one as there are currently no effective targeted treatments for the aggressive form of this disease (that Talan had).

Talan’s Trust are determined to help change this.

Since Talan died in May 2017 the supporters of Talan’s Trust have raised over £30,000. This money will be used (via the Chris Lucas Trust) to support the work of a full time RMS researcher, working at the Royal Marsden Hospital.

The Chris Lucas Trust was set up in memory of another teenage boy who died from RMS in July 2000. Since Chris’ death, his parents – Lynn and Lynn Lucas – have raised over £2million for research into the disease. Talan’s Trust are very proud to be able to contribute towards this research.

In December 2018, we were delighted to visit the Institute of Cancer Research at the Royal Marsden Hospital and to meet the researchers working on RMS. We attended with Lynn and Lynn Lucas from the Chris Lucas Trust and were given an excellent presentation about current research into rhabdomyosarcoma. We then visited the research laboratory, we were also shown some of the work which the team are doing to find a cure for this particular type of sarcoma cancer.

Why is the research needed? 

The Chris Lucas Trust explains:

Little is known about the underlying biology of childhood cancers, and children still tend to be treated with older-style, un-specific and toxic chemotherapy drugs designed for adults, so the side-effects can be harmful. We believe the way to improve outcomes for children with poor-prognosis cancers is to support research to understand the whole disease process, from the initial genetic changes to the molecular features of tumours themselves, and to use this information to pinpoint new treatment targets on the tumour cells.

This will enable the development of new targeted therapies which are more precise in their action and less likely to cause side-effects. Our scientists then seek to either match an existing targeted therapy to the tumour or, if one does not exist, to design a new one. Our aim is to develop tailored treatments for all children, in the fastest possible time, with maximum benefit and minimum side-effects.